Anti-LRRC15 Antibodies and Antibody-Drug Conjugates (ADCs)

These two related patents cover the development and application of anti-LRRC15 antibodies for cancer therapy. They represent a unified research effort yielding both the foundational antibodies and their specific application as drug conjugates.

• WO/2026/112469: ANTI-LRRC15 ANTIBODIES AND USES THEREOF. Provides isolated anti-LRRC15 antibodies, including bispecific antibodies and ADCs, that specifically bind to and are internalized by cells expressing LRRC15. Includes methods for treating cancer and diagnostic uses.
• WO/2026/112472: ANTI-LRRC15 ANTIBODY DRUG CONJUGATES. Focuses specifically on ADCs where an anti-LRRC15 antibody is conjugated to exatecan via a linker. It details the chemical formulas of these conjugates and specific methods for cancer treatment by administering these ADCs.

Publication Date: May 28, 2026
Assignee: Bristol Myers Squibb

Recommended citation: Bristol Myers Squibb (Co-inventor: Yuntao Zhang). (2026). "Anti-LRRC15 Antibodies and Antibody-Drug Conjugates." WIPO Patent Publication Nos. WO/2026/112469 and WO/2026/112472.
Download Paper | Download Slides | Download Bibtex